Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors

ACS Medicinal Chemistry Letters
2022.0

Abstract

For the first time, derivatives of 3,7-diazabicyclo[3.3.1]nonane (bispidine) were proposed as potential inhibitors of the SARS-CoV-2 main viral protease (3-chymotrypsin-like, 3CLpro). Based on the created pharmacophore model of the active site of the protease, a group of compounds were modeled and tested for activity against 3CLpro. The 3CLpro activity was measured using the fluorogenic substrate Dabcyl-VNSTLQSGLRK(FAM)MA; the efficiency of the proposed approach was confirmed by comparison with literature data for ebselen and disulfiram. The results of the experiments performed with bispidine compounds showed that 14 compounds exhibited activity in the concentration range 1-10 μM, and 3 samples exhibited submicromolar activity. The structure-activity relationship studies showed that the molecules containing a carbonyl group in the ninth position of the bicycle exhibited the maximum activity. Based on the experimental and theoretical results obtained, further directions for the development of this topic were proposed.

Knowledge Graph

Similar Paper

Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors
ACS Medicinal Chemistry Letters 2022.0
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
ACS Medicinal Chemistry Letters 2020.0
Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro)
European Journal of Medicinal Chemistry 2023.0
Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CL<sup>Pro</sup> Inhibitors: In Silico Molecular Docking, Molecular Dynamics, and In Vitro Enzymatic Activity
Journal of Chemical Information and Modeling 2023.0
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19
European Journal of Medicinal Chemistry 2022.0
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Journal of Medicinal Chemistry 2022.0
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease
European Journal of Medicinal Chemistry 2022.0
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency
ACS Medicinal Chemistry Letters 2021.0
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2022.0
Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach
Journal of Natural Products 2023.0